교모세포종 치료제 시장 : 규모, 점유율, 성장, 산업 분석, 지역 인사이트 및 예측(2026-2034년)

Growth Factors of glioblastoma drugs Market

The global glioblastoma drugs market was valued at USD 0.79 billion in 2025 and is projected to grow from USD 0.83 billion in 2026 to USD 1.21 billion by 2034, registering a CAGR of 4.82% during the forecast period. The market growth is primarily driven by the increasing prevalence of glioblastoma, growing investments in oncology drug development, rising adoption of combination therapies, and the expansion of immunotherapy-based treatment pipelines. Despite the aggressive nature of glioblastoma and limited long-term treatment success, pharmaceutical companies continue to invest heavily in innovative therapies aimed at improving patient survival outcomes.

North America dominated the global glioblastoma drugs market in 2025, accounting for 37.97% of the total market revenue due to its advanced neuro-oncology infrastructure, strong clinical trial ecosystem, and high treatment adoption rates.

Market Size and Forecast

• 2025 Market Size: USD 0.79 Billion
• 2026 Market Size: USD 0.83 Billion
• 2034 Market Size: USD 1.21 Billion
• CAGR (2026-2034): 4.82%

The growing burden of brain tumors and increasing research into targeted therapies and immune-based treatments are expected to create sustainable growth opportunities across the forecast period.

Key Market Trends

Rising Focus on Immunotherapy-Based Treatments

One of the most significant trends shaping the glioblastoma drugs market is the increasing development of immunotherapy-based therapies. Traditional treatments such as surgery, radiation, and chemotherapy continue to dominate clinical practice, but their effectiveness remains limited, especially in recurrent disease.

As a result, pharmaceutical companies are increasingly investing in:

• Cancer vaccines
• Cell-based immunotherapies
• Immune checkpoint inhibitors
• Personalized tumor-specific therapies

For example, in December 2025, Imvax announced positive Phase 2b trial results for IGV-001, a patient-specific whole-tumor-cell immunotherapy developed for newly diagnosed glioblastoma patients.

Market Drivers

High Unmet Need for Effective Therapies

Glioblastoma remains one of the most aggressive and difficult-to-treat brain cancers. Existing therapies offer limited survival benefits and recurrence rates remain extremely high.

Growing demand for more effective treatments is encouraging companies to accelerate clinical development activities and seek regulatory support. In October 2025, Myosin Therapeutics received U.S. FDA Fast Track designation for MT-125, highlighting increasing regulatory encouragement for innovative glioblastoma therapies.

Market Restraints

Rapid Treatment Resistance and Disease Recurrence

One of the major barriers to market growth is the rapid development of treatment resistance. Most patients experience disease recurrence even after undergoing surgery, radiation, and chemotherapy.

Resistance to standard therapies such as temozolomide reduces long-term treatment effectiveness and creates significant challenges for developers attempting to demonstrate meaningful survival benefits in clinical trials.

Market Opportunities

Expanding Clinical Pipeline

The market is witnessing substantial pipeline activity, creating long-term growth opportunities. Numerous investigational therapies targeting novel biological pathways are entering clinical development.

In August 2025, Lantern Pharma's subsidiary Starlight Therapeutics received FDA clearance to initiate a Phase Ib/2a clinical study for glioblastoma, reflecting the industry's continued commitment to addressing unmet treatment needs.

Market Challenges

Tumor Heterogeneity

Glioblastoma exhibits significant biological variability among patients and even within individual tumors. This heterogeneity complicates treatment development and reduces the likelihood of a single therapy being effective across the broader patient population.

As a result, drug developers face complex clinical trial designs, increased development risks, and challenges in identifying responsive patient groups.

Segment Analysis

By Drug

The Temozolomide segment dominated the market in 2025 due to its established role as the standard first-line chemotherapy for glioblastoma treatment.

The Others segment is expected to register the fastest growth with a CAGR of 8.50% during the forecast period.

By Drug Class

Alkylating Agents held the largest market share owing to widespread use of temozolomide-based treatment regimens.

The Immune Checkpoint Inhibitors segment is projected to grow at a CAGR of 11.92% through 2034.

By Age Group

The Adult segment dominated the market due to the significantly higher incidence of glioblastoma among adults.

The Pediatric segment is expected to grow at a CAGR of 7.61%.

By Type

The Generic Drugs segment accounted for the largest share due to broad availability and lower treatment costs.

By Therapy

Chemotherapy remained the leading therapy segment in 2025, supported by continued reliance on temozolomide-based treatment protocols.

The Immunotherapy segment is expected to witness the fastest growth at a CAGR of 12.72%.

By Route of Administration

The Oral segment dominated the market because temozolomide is primarily administered orally, improving patient convenience and treatment adherence.

By Distribution Channel

Hospital Pharmacies accounted for the largest market share owing to the specialized nature of glioblastoma treatment and hospital-centered care pathways.

Regional Analysis

North America

• 2025 Market Value: USD 0.30 Billion
• Largest regional market in 2025

The region benefits from advanced healthcare infrastructure, strong oncology research activities, and extensive clinical trial participation.

Europe

• 2026 Market Value: USD 0.23 Billion

Europe continues to expand due to strong public healthcare systems and increasing access to advanced cancer therapies.

Asia Pacific

• 2026 Market Value: USD 0.19 Billion

Growth is supported by improving cancer treatment infrastructure and increasing investments in oncology research.

Key Country Insights (2026)

• U.S.: USD 0.29 Billion
• China: USD 0.08 Billion
• Germany: USD 0.05 Billion
• U.K.: USD 0.05 Billion
• Japan: USD 0.04 Billion
• India: USD 0.02 Billion

Competitive Landscape

The market remains highly consolidated with major players focusing on product launches, clinical trials, partnerships, and pipeline expansion.

Key companies include:

• Merck & Co., Inc.
• Genentech, Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Accord Healthcare
• Camber Pharmaceuticals, Inc.
• Fresenius Kabi AG
• Zydus Lifesciences Ltd.

Recent industry developments include multiple clinical trial initiations, FDA designations, novel immunotherapy advancements, and genomic testing collaborations aimed at improving treatment outcomes.

Conclusion

The global glioblastoma drugs market is expected to experience steady growth from USD 0.79 billion in 2025 to USD 1.21 billion by 2034. Rising incidence of brain tumors, increasing investment in immunotherapy and targeted therapies, and a robust clinical pipeline are driving market expansion. While challenges such as tumor heterogeneity, treatment resistance, and high recurrence rates remain significant, continued innovation and regulatory support are expected to improve therapeutic options and create new growth opportunities throughout the forecast period.

Segmentation By Drug, Drug Class, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Region

By Drug * Temozolomide

• Bevacizumab
• Carmustine
• Lomustine
• Procarbazine
• Irinotecan
• Others

By Drug Class * Alkylating agents

• VEGF / angiogenesis inhibitors
• Nitrosoureas
• Platinum compounds
• Topoisomerase inhibitors
• Immune checkpoint inhibitors
• Others

By Age Group * Pediatric

• Adults

By Type * Branded

• Generic

By Therapy * Targeted Therapy

• Immunotherapy
• Chemotherapy
• Others

By Route of Administration * Oral

• Parenteral

By Distribution Channel * Hospital pharmacies

• Drug stores & retail pharmacies
• Online pharmacies

By Region * North America (By Drug, Drug Class, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country)

• U.S.
• Canada
• Europe (By Drug, Drug Class, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug, Drug Class, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug, Drug Class, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug, Drug Class, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Cancer, By Key Indication, By Key Countries /Regions
• 4.2. New Product Launches, By Key Players
• 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
• 4.4. Regulatory Scenario, By Key Countries/Regions

5. Global Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug
  • 5.1.1. Temozolomide
  • 5.1.2. Bevacizumab
  • 5.1.3. Carmustine
  • 5.1.4. Lomustine
  • 5.1.5. Procarbazine
  • 5.1.6. Irinotecan
  • 5.1.7. Others
• 5.2. Market Analysis, Insights and Forecast - By Drug Class
  • 5.2.1. Alkylating Agents
  • 5.2.2. VEGF/Angiogenesis Inhibitors
  • 5.2.3. Nitrosoureas
  • 5.2.4. Platinum Compounds
  • 5.2.5. Topoisomerase Inhibitors
  • 5.2.6. Immune Checkpoint Inhibitors
  • 5.2.7. Others
• 5.3. Market Analysis, Insights and Forecast - By Age Group
  • 5.3.1. Pediatric
  • 5.3.2. Adults
• 5.4. Market Analysis, Insights and Forecast - By Type
  • 5.4.1. Branded
  • 5.4.2. Generic
• 5.5. Market Analysis, Insights and Forecast - By Therapy
  • 5.5.1. Targeted therapy
  • 5.5.2. Immunotherapy
  • 5.5.3. Chemotherapy
  • 5.5.4. Others
• 5.6. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.6.1. Oral
  • 5.6.2. Parenteral
• 5.7. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.7.1. Hospital Pharmacies
  • 5.7.2. Drug Stores & Retail Pharmacies
  • 5.7.3. Online Pharmacies
• 5.8. Market Analysis, Insights and Forecast - Region
  • 5.8.1. North America
  • 5.8.2. Europe
  • 5.8.3. Asia Pacific
  • 5.8.4. Latin America
  • 5.8.5. Middle East & Africa

6. North America Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug
  • 6.1.1. Temozolomide
  • 6.1.2. Bevacizumab
  • 6.1.3. Carmustine
  • 6.1.4. Lomustine
  • 6.1.5. Procarbazine
  • 6.1.6. Irinotecan
  • 6.1.7. Others
• 6.2. Market Analysis, Insights and Forecast - By Drug Class
  • 6.2.1. Alkylating Agents
  • 6.2.2. VEGF/Angiogenesis Inhibitors
  • 6.2.3. Nitrosoureas
  • 6.2.4. Platinum Compounds
  • 6.2.5. Topoisomerase Inhibitors
  • 6.2.6. Immune Checkpoint Inhibitors
  • 6.2.7. Others
• 6.3. Market Analysis, Insights and Forecast - By Age Group
  • 6.3.1. Pediatric
  • 6.3.2. Adults
• 6.4. Market Analysis, Insights and Forecast - By Type
  • 6.4.1. Branded
  • 6.4.2. Generic
• 6.5. Market Analysis, Insights and Forecast - By Therapy
  • 6.5.1. Targeted therapy
  • 6.5.2. Immunotherapy
  • 6.5.3. Chemotherapy
  • 6.5.4. Others
• 6.6. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.6.1. Oral
  • 6.6.2. Parenteral
• 6.7. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.7.1. Hospital Pharmacies
  • 6.7.2. Drug Stores & Retail Pharmacies
  • 6.7.3. Online Pharmacies
• 6.8. Market Analysis, Insights and Forecast - By Country
  • 6.8.1. U.S.
  • 6.8.2. Canada

7. Europe Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug
  • 7.1.1. Temozolomide
  • 7.1.2. Bevacizumab
  • 7.1.3. Carmustine
  • 7.1.4. Lomustine
  • 7.1.5. Procarbazine
  • 7.1.6. Irinotecan
  • 7.1.7. Others
• 7.2. Market Analysis, Insights and Forecast - By Drug Class
  • 7.2.1. Alkylating Agents
  • 7.2.2. VEGF/Angiogenesis Inhibitors
  • 7.2.3. Nitrosoureas
  • 7.2.4. Platinum Compounds
  • 7.2.5. Topoisomerase Inhibitors
  • 7.2.6. Immune Checkpoint Inhibitors
  • 7.2.7. Others
• 7.3. Market Analysis, Insights and Forecast - By Age Group
  • 7.3.1. Pediatric
  • 7.3.2. Adults
• 7.4. Market Analysis, Insights and Forecast - By Type
  • 7.4.1. Branded
  • 7.4.2. Generic
• 7.5. Market Analysis, Insights and Forecast - By Therapy
  • 7.5.1. Targeted therapy
  • 7.5.2. Immunotherapy
  • 7.5.3. Chemotherapy
  • 7.5.4. Others
• 7.6. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.6.1. Oral
  • 7.6.2. Parenteral
• 7.7. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.7.1. Hospital Pharmacies
  • 7.7.2. Drug Stores & Retail Pharmacies
  • 7.7.3. Online Pharmacies
• 7.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.8.1. U.K.
  • 7.8.2. Germany
  • 7.8.3. France
  • 7.8.4. Italy
  • 7.8.5. Spain
  • 7.8.6. Scandinavia
  • 7.8.7. Rest of Europe

8. Asia Pacific Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug
  • 8.1.1. Temozolomide
  • 8.1.2. Bevacizumab
  • 8.1.3. Carmustine
  • 8.1.4. Lomustine
  • 8.1.5. Procarbazine
  • 8.1.6. Irinotecan
  • 8.1.7. Others
• 8.2. Market Analysis, Insights and Forecast - By Drug Class
  • 8.2.1. Alkylating Agents
  • 8.2.2. VEGF/Angiogenesis Inhibitors
  • 8.2.3. Nitrosoureas
  • 8.2.4. Platinum Compounds
  • 8.2.5. Topoisomerase Inhibitors
  • 8.2.6. Immune Checkpoint Inhibitors
  • 8.2.7. Others
• 8.3. Market Analysis, Insights and Forecast - By Age Group
  • 8.3.1. Pediatric
  • 8.3.2. Adults
• 8.4. Market Analysis, Insights and Forecast - By Type
  • 8.4.1. Branded
  • 8.4.2. Generic
• 8.5. Market Analysis, Insights and Forecast - By Therapy
  • 8.5.1. Targeted therapy
  • 8.5.2. Immunotherapy
  • 8.5.3. Chemotherapy
  • 8.5.4. Others
• 8.6. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.6.1. Oral
  • 8.6.2. Parenteral
• 8.7. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.7.1. Hospital Pharmacies
  • 8.7.2. Drug Stores & Retail Pharmacies
  • 8.7.3. Online Pharmacies
• 8.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.8.1. China
  • 8.8.2. Japan
  • 8.8.3. India
  • 8.8.4. Southeast Asia
  • 8.8.5. Australia
  • 8.8.6. Rest of Asia Pacific

9. Latin America Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug
  • 9.1.1. Temozolomide
  • 9.1.2. Bevacizumab
  • 9.1.3. Carmustine
  • 9.1.4. Lomustine
  • 9.1.5. Procarbazine
  • 9.1.6. Irinotecan
  • 9.1.7. Others
• 9.2. Market Analysis, Insights and Forecast - By Drug Class
  • 9.2.1. Alkylating Agents
  • 9.2.2. VEGF/Angiogenesis Inhibitors
  • 9.2.3. Nitrosoureas
  • 9.2.4. Platinum Compounds
  • 9.2.5. Topoisomerase Inhibitors
  • 9.2.6. Immune Checkpoint Inhibitors
  • 9.2.7. Others
• 9.3. Market Analysis, Insights and Forecast - By Age Group
  • 9.3.1. Pediatric
  • 9.3.2. Adults
• 9.4. Market Analysis, Insights and Forecast - By Type
  • 9.4.1. Branded
  • 9.4.2. Generic
• 9.5. Market Analysis, Insights and Forecast - By Therapy
  • 9.5.1. Targeted therapy
  • 9.5.2. Immunotherapy
  • 9.5.3. Chemotherapy
  • 9.5.4. Others
• 9.6. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.6.1. Oral
  • 9.6.2. Parenteral
• 9.7. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.7.1. Hospital Pharmacies
  • 9.7.2. Drug Stores & Retail Pharmacies
  • 9.7.3. Online Pharmacies
• 9.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.8.1. Brazil
  • 9.8.2. Mexico
  • 9.8.3. Rest of Latin America

10. Middle East & Africa Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug
  • 10.1.1. Temozolomide
  • 10.1.2. Bevacizumab
  • 10.1.3. Carmustine
  • 10.1.4. Lomustine
  • 10.1.5. Procarbazine
  • 10.1.6. Irinotecan
  • 10.1.7. Others
• 10.2. Market Analysis, Insights and Forecast - By Drug Class
  • 10.2.1. Alkylating Agents
  • 10.2.2. VEGF/Angiogenesis Inhibitors
  • 10.2.3. Nitrosoureas
  • 10.2.4. Platinum Compounds
  • 10.2.5. Topoisomerase Inhibitors
  • 10.2.6. Immune Checkpoint Inhibitors
  • 10.2.7. Others
• 10.3. Market Analysis, Insights and Forecast - By Age Group
  • 10.3.1. Pediatric
  • 10.3.2. Adults
• 10.4. Market Analysis, Insights and Forecast - By Type
  • 10.4.1. Branded
  • 10.4.2. Generic
• 10.5. Market Analysis, Insights and Forecast - By Therapy
  • 10.5.1. Targeted therapy
  • 10.5.2. Immunotherapy
  • 10.5.3. Chemotherapy
  • 10.5.4. Others
• 10.6. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.6.1. Oral
  • 10.6.2. Parenteral
• 10.7. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.7.1. Hospital Pharmacies
  • 10.7.2. Drug Stores & Retail Pharmacies
  • 10.7.3. Online Pharmacies
• 10.8. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.8.1. GCC
  • 10.8.2. South Africa
  • 10.8.3. Rest of the Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Merck & Co., Inc.
  • 11.2.2. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
  • 11.2.3. Teva Pharmaceutical Industries Ltd.
  • 11.2.4. Sun Pharmaceutical Industries Ltd.
  • 11.2.5. Accord Healthcare
  • 11.2.6. Camber Pharmaceuticals, Inc.
  • 11.2.7. Fresenius Kabi AG
  • 11.2.8. Zydus Lifesciences Ltd.
  • 11.2.9. Amneal Pharmaceuticals, Inc.